Thomas Bochaton
Overview
Explore the profile of Thomas Bochaton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Badawi S, Leboullenger C, Chourrout M, Gouriou Y, Paccalet A, Pillot B, et al.
Basic Res Cardiol
. 2024 Mar;
119(3):435-451.
PMID: 38499702
Myocardial infarction (MI) is a serious acute cardiovascular syndrome that causes myocardial injury due to blood flow obstruction to a specific myocardial area. Under ischemic-reperfusion settings, a burst of reactive...
12.
Fauvel C, Dillinger J, Bochaton T, Mansencal N, Noirclerc N, Schurtz G, et al.
JACC Heart Fail
. 2024 Feb;
12(5):967-969.
PMID: 38363274
No abstract available.
13.
Leboube S, Camboulives L, Bochaton T, Amaz C, Bergerot C, Altman M, et al.
Front Cardiovasc Med
. 2024 Feb;
10:1290375.
PMID: 38322272
Background: Women are more likely to develop heart failure (HF) after myocardial infarction. However, diagnosis and reperfusion are often delayed. Objectives: To compare the prevalence of HF after primary percutaneous...
14.
Dietz M, Bochaton T, Al Mansour L, Tordo J, Flaus A
J Nucl Cardiol
. 2024 Jan;
32:101812.
PMID: 38246257
No abstract available.
15.
Bouleti C, Viscogliosi S, Bresson D, Leboube S, Bochaton T, El-Jonhy N, et al.
Open Heart
. 2024 Jan;
11(1).
PMID: 38233042
Objective: In the COVERT-MI randomised placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days in acute ST-elevated myocardial infarction did not reduce infarct...
16.
Schurtz G, Mewton N, Lemesle G, Delmas C, Levy B, Puymirat E, et al.
Front Cardiovasc Med
. 2023 Dec;
10:1263482.
PMID: 38050613
The role of the beta-adrenergic signaling pathway in heart failure (HF) is pivotal. Early blockade of this pathway with beta-blocker (BB) therapy is recommended as the first-line medication for patients...
17.
Derimay F, Aminian A, Lattuca B, Souteyrand G, Maillard L, Alvain S, et al.
Int J Cardiol
. 2023 Dec;
397:131632.
PMID: 38048882
Background: Re-POT (proximal optimization technique (POT)) is a simple provisional sequential technique for percutaneous coronary bifurcation revascularization with better arterial geometry respect compared to classical techniques. Re-POT has demonstrated excellent...
18.
Brun C, Chalet L, Moulin F, Bochaton T, Ducreux S, Paillard M, et al.
Front Immunol
. 2023 Oct;
14:1272809.
PMID: 37901222
Background: The immune system, composed of organs, tissues, cells, and proteins, is the key to protecting the body from external biological attacks and inflammation. The latter occurs in several pathologies,...
19.
Miquelestorena-Standley E, Vinhais da Silva A, Monnier M, Chadet S, Piollet M, Heraud A, et al.
Sci Rep
. 2023 Oct;
13(1):16745.
PMID: 37798364
Pathophysiological response after acute myocardial infarction (AMI) is described as a three-stage model involving temporal phenotypic modifications of both immune cells and fibroblasts: a primary inflammatory phase, followed by a...
20.
Pezel T, Dillinger J, Trimaille A, Delmas C, Piliero N, Bouleti C, et al.
Heart
. 2023 Aug;
109(21):1608-1616.
PMID: 37582633
Objective: While recreational drug use is a risk factor for cardiovascular events, its exact prevalence and prognostic impact in patients admitted for these events are not established. We aimed to...